Block Polymer Heparin Neutralization via Electrostatic Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for heparin neutralization, such as protamine and physical removal devices, often result in adverse effects and are inefficient, particularly for low-molecular-weight heparins, which lack effective antidotes and have prolonged action, making it difficult to reverse anticoagulation in patients.
Innovation Solution
The use of synthetic block polymers, specifically PEG-PMAPTAC and PMPC-PMAPTAC copolymers, obtained through controlled radical polymerization, for direct neutralization of heparins in blood and physiological fluids, providing a safer and more efficient alternative to existing methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protamine is used for heparin neutralization, then heparin action is neutralized, but adverse effects occur in about 10% of patients including pulmonary hypertension, arterial hypotension, anaphylactic shock, thrombocytopenia and granulocytopenia
Solution Approach 1:
The patent changes the chemical parameters of the neutralizing agent by using synthetic block polymers with specific sequences (PEG-PMAPTAC or PMPC-PMAPTAC) instead of natural protamine. These polymers have controlled molecular weight, composition, and structure that enable effective heparin neutralization without the adverse effects associated with protamine, such as pulmonary hypertension, hypotension, and anaphylactic reactions.
Solution Approach 2:
The patent employs composite block copolymer structures combining different polymer blocks (e.g., PEG block with PMAPTAC block, or PMPC block with PMAPTAC block) to achieve both biocompatibility and effective heparin binding. This composite approach allows the polymer to neutralize heparin while maintaining safety profile superior to protamine.
2Reliability
If protamine is used for heparin neutralization, then unfractionated heparin is neutralized, but low-molecular-weight heparins show only partial neutralization (up to 60% maximum)
Solution Approach 1:
The synthetic block polymers (PEG-PMAPTAC and PMPC-PMAPTAC) are designed with universal binding capability that works effectively against both unfractionated heparin and low-molecular-weight heparins. The polymer structure allows it to neutralize different types of heparin molecules, providing comprehensive coverage across the entire heparin spectrum, unlike protamine which only partially neutralizes LMWH.
3Reliability
If physical removal devices based on immobilized poly-L-lysine are used, then heparin is removed from blood, but the devices are uncomfortable and impractical due to limitations in application requiring hospitalization
Solution Approach 1:
The patent replaces complex mechanical removal devices with a simple pharmacological solution using soluble block polymers. Instead of requiring extracorporeal circuits, filters, or immobilized columns that need hospitalization and complex operation, the synthetic polymers can be administered intravenously to neutralize heparin directly in the blood, greatly simplifying the application process and eliminating the need for specialized equipment and hospitalization.
4Object-affected harmful factors
If low-molecular-weight heparins are used, then safer profile with prolonged action is achieved, but no effective antidote exists and it is more difficult to return normal blood coagulation when overdosed
Solution Approach 1:
The synthetic block polymers serve as an intermediary substance that can neutralize low-molecular-weight heparins. These polymers act as a bridge between the patient and the excess heparin, binding to the anticoagulant molecules and reversing their effect. This provides the first effective antidote for LMWH, enabling safe use of these drugs with the ability to reverse their action when needed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These block polymers effectively neutralize both unfractionated and low-molecular-weight heparins without adverse effects, as demonstrated by their ability to restore normal coagulation parameters and reduce thrombus formation, offering a safer and more practical solution compared to traditional methods.
Implementation Method 1
Heparin is a glycosaminoglycan (GAG) with a large molecular weight dispersity and high degree of substitution with sulfate groups (it has the largest density of a negative charge among biomolecules reaching 2.7 charges per a repeat unit)... The block polymer... for the neutralization of heparin
Data Source
Figure 1
Figure 1
Figure 2~3
AI summary
The subject of the invention is use of block polymers with a block of poly(3-methacryloylpropyltrimethylammonium chloride) to direct neutralization of heparin, especially unfractionated heparin and low molecular weight heparins in the blood and other body fluids.